[76] This strategy gives specificity, stability and target delivery.[77] The function of PMOs is blocking the interaction of proteins with the target RNA. This method has been applied against the L gene of hRSV to impair infection RAD001 nmr in cell lines and in animal models.[76] There are limited options of prophylaxis and currently no vaccines are available to prevent hRSV infection (Table 2). Current clinical approaches to control hRSV infection comprise passive immunization with neutralizing antibodies against F and G proteins, which has been successful at decreasing the symptoms of hRSV infection. Further, these strategies

can reduce the severe detrimental effects caused by hRSV infection in patients with risk factors, who can develop serious illness.[78, 79] A humanized monoclonal antibody that prevents hRSV fusion to the host cells by the neutralizing F protein (palivizumab or Synagis®; MedImmune, Gaithersburg, MD), is the most efficient and used antibody to prevent severe cases of hRSV disease.[80, 81] Motavizumab is another humanized antibody that binds the fusion protein after attachment to the host cell, but before starting the transcription of the viral MK-1775 genome.[82, 83] Neither monoclonal antibody completely prevents viral entry to

the host cell but they decrease the viral replication and prevent hRSV infection. Despite the effectiveness of palivizumab in the treatment of hRSV infection, the use of this drug is seriously limited due to high costs and is restricted to patients with high risk of severe bronchiolitis associated with congenital diseases and preterm birth.[84] Safety, Tolerability and Immunogenicity of MEDI-524 After Dosing for a Second Season complete Phase 1-III, complete The

development of an efficient vaccine against hRSV requires that the formulation Oxalosuccinic acid promotes protective and efficient immunity against the virus, without adverse effects. Human RSV proteins are immunogenic and are good candidates to design vaccines, but it is important to consider that some hRSV proteins or peptides can negatively modulate the host immune response.[85] Further, an efficient vaccine candidate has to prevent the Th2 immune response and needs to promote viral clearance before the development of the disease.[85] Vectors comprising hRSV genes or parts of the genome of this virus have been used as DNA vaccines, in combination with adjuvants that promote Th1 immunity. An example of this approach is an hRSV-G construct that induces neutralizing antibodies to balance the production of pulmonary Th1/Th2 cytokines during hRSV infection.[86] The gene coding for the F protein has also been used as a DNA vaccine, an example of this approach is the insert of the F gene into the Newcastle disease virus vector (NDV-F).